NASDAQ:GANX - Nasdaq - US36269B1052 - Common Stock - Currency: USD
NASDAQ:GANX (5/9/2025, 8:00:01 PM)
1.94
-0.08 (-4.2%)
The current stock price of GANX is 1.94 USD. In the past month the price increased by 22.78%. In the past year, price decreased by -22.71%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.97 | 326.55B | ||
AMGN | AMGEN INC | 12.81 | 142.94B | ||
GILD | GILEAD SCIENCES INC | 12.52 | 120.65B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 109.26B | ||
REGN | REGENERON PHARMACEUTICALS | 11.91 | 56.98B | ||
ARGX | ARGENX SE - ADR | 93.64 | 33.56B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.67B | ||
ONC | BEIGENE LTD-ADR | 5.79 | 25.01B | ||
BNTX | BIONTECH SE-ADR | N/A | 22.30B | ||
NTRA | NATERA INC | N/A | 20.66B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
BIIB | BIOGEN INC | 7.47 | 17.32B |
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 23 full-time employees. The company went IPO on 2021-03-18. The firm is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
GAIN THERAPEUTICS INC
4800 Montgomery Lane, Suite 220
Bethesda MARYLAND 20814 US
CEO: Eric Richman
Employees: 31
Phone: 13015001556
The current stock price of GANX is 1.94 USD. The price decreased by -4.2% in the last trading session.
The exchange symbol of GAIN THERAPEUTICS INC is GANX and it is listed on the Nasdaq exchange.
GANX stock is listed on the Nasdaq exchange.
13 analysts have analysed GANX and the average price target is 8.16 USD. This implies a price increase of 320.62% is expected in the next year compared to the current price of 1.94. Check the GAIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GAIN THERAPEUTICS INC (GANX) has a market capitalization of 57.09M USD. This makes GANX a Micro Cap stock.
GAIN THERAPEUTICS INC (GANX) currently has 31 employees.
GAIN THERAPEUTICS INC (GANX) has a support level at 1.9 and a resistance level at 1.96. Check the full technical report for a detailed analysis of GANX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GANX does not pay a dividend.
GAIN THERAPEUTICS INC (GANX) will report earnings on 2025-08-06.
GAIN THERAPEUTICS INC (GANX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.92).
The outstanding short interest for GAIN THERAPEUTICS INC (GANX) is 1.06% of its float. Check the ownership tab for more information on the GANX short interest.
ChartMill assigns a technical rating of 3 / 10 to GANX. When comparing the yearly performance of all stocks, GANX is a bad performer in the overall market: 81.87% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to GANX. Both the profitability and financial health of GANX have multiple concerns.
Over the last trailing twelve months GANX reported a non-GAAP Earnings per Share(EPS) of -0.92. The EPS increased by 48.31% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -168.36% | ||
ROE | -278.1% | ||
Debt/Equity | 0.04 |
ChartMill assigns a Buy % Consensus number of 85% to GANX. The Buy consensus is the average rating of analysts ratings from 13 analysts.